6986.Two

6986.TWO has a strong liquidity position, with a current ratio of 9.75, indicating that the company holds significantly more current assets than current liabilities. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of TWD 27,010,000 and a free cash flow of TWD 112,253,000. However, the company has a net cash position that is negative after subtracting total debt, which may pose a liquidity risk in the short term.

In terms of profitability, 6986.TWO demonstrates a return on equity (ROE) of 15.09% and a return on assets (ROA) of 13.37%, both of which are strong indicators of efficient use of equity and assets. The company's gross profit margin is 90.8%, and its operating margin is 40.26%, which are both well above the industry median for biotechnology and medical research firms. These metrics suggest that the company is effectively managing its costs and generating substantial operating income relative to its revenue.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of geographic diversification may expose the company to regional economic or regulatory risks, although the data does not specify the geographic distribution of its revenue.

Looking at the company's growth trajectory, the outlook for the current fiscal year is positive, with a projected increase in revenue and earnings. The company's revenue is expected to grow by a double-digit percentage, driven by continued demand for its diagnostic products and services. The next fiscal year is also expected to show growth, although the exact percentage is not specified in the available data.

The risk assessment for 6986.TWO indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.05, which is relatively low, suggesting that the company is not heavily leveraged. However, the negative net cash position after subtracting total debt is a concern, as it may indicate that the company is using more cash than it is generating. The company has not made any recent equity issuances or share buybacks, and there is no indication of dilution pressure in the near term.

Recent events and filings for 6986.TWO do not include any significant corporate actions or earnings surprises. The company has not issued any new products or services in the recent period, and there are no notable changes in management or strategic direction. The company's financial performance has been consistent, with no major deviations in revenue or earnings from the previous periods.